

Associate Professor Natalie Walker

Publications

Refereed Journal Articles:

1. Joo YJ, Newcombe D, Nosa V, **Walker N**, Bullen C. Betel Nut Use in Vanuatu: Investigating Opportunities to Reduce Harms to Health. *Subst Use Misuse* 2020; 55:9, 1457-1464, doi: 10.1080/10826084.2020.1716803
2. Gao TY, Black, JM, Babu RJ, Bobier WR, Chakraborty A, Dai S, Guo CX, Hess, RF, Jenkins M, Jiang Y, Kearns LS, Kowal L, Lam CSY, Pang PCK, Parag V, Pieri R, Raveendren RN, South J, Staffieri SE, Wadham A, **Walker N**, Thompson B on behalf of the Binocular Treatment of Amblyopia Using Videogames (BRAVO) Study Team. Adherence to home-based videogame treatment for amblyopia in children and adults. *Clin Exp Optometry* 2020 (MedRxiv, 2020: doi: <https://doi.org/10.1101/2020.05.25.20113126>).
3. Galea-Singer S, Newcombe D, Farnsworth-Grodd V, Sheridan J, Adams P, **Walker N**. Challenges of virtual talking therapies for substance misuse in New Zealand during the COVID-19 Pandemic: An Opinion Piece. *NZ Med J* 2020; 22 May; 133 (1515).
4. **Walker N**, Parag V, Wong S, Youdan B, Broughton B, Bullen C, Beaglehole R. Daily use of e-cigarettes and smoked tobacco in youth aged 14-15 years in New Zealand: findings from repeated cross-sectional studies (2014-2019). *Lancet Public Health* 2020; Jan 21. pii: S2468-2667(19)30241-5. doi: 10.1016/S2468-2667(19)30241-5.
5. Piper ME, Drobes DJ, **Walker N**. Behavioral and Subjective Effects of Reducing Nicotine in Cigarettes: A Cessation Commentary. *Nicotine Tob Res* 2019; 21 (S1): S19–S21, <https://doi.org/10.1093/ntr/ntz100>
6. **Walker N**, Parag V, Verbiest M, Laking G, Laugesen M, Bullen C. Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic randomised trial. *Lancet Resp Med*, 2020: 8 (1): 54-64. Online September 9, 2019 [http://dx.doi.org/10.1016/S2213-2600\(19\)30269-3](http://dx.doi.org/10.1016/S2213-2600(19)30269-3).
7. Barnes J, McRobbie H, Dong CY, **Walker N**, Hartmann-Boyce J. Hypnotherapy for smoking cessation. *Cochrane Database of Systematic Reviews* 2019, Issue 6. Art. No.: CD001008. DOI: 10.1002/14651858.CD001008.pub3.
8. Vaghefi E, Yang S, Hill S, Humphrey G, **Walker N**, Squirrell D. Detection of smoking status from retinal images; a Convolutional Neural Network study. *Sci. Rep.* 2019; 9 (7180): s41598-019-43670-0
9. **Walker N**, Verbiest M, Kurdziel T, Laking G, Laugesen M, Parag V, Bullen C. Effectiveness and safety of nicotine patches combined with e-cigarettes (with and without nicotine) for smoking cessation: Study protocol for a randomised controlled trial. *BMJ Open*, 2019:9 (2): e023659. doi:10.1136/bmjopen-2018-023659

10. Jeong S-H, Sheridan J, Bullen C, Newcombe D, **Walker N**, Tingle M. Ascending single dose pharmacokinetics of cytisine in healthy adult smokers, *Xenobiotica*, 2019, DOI: 10.1080/00498254.2018.1557760
11. **Walker N**, Smith B, Barnes J, Verbiest M, Kurdziel T, Parag V, Pokhrel S, Bullen C. Cytisine versus varenicline for smoking cessation in Māori (the indigenous people of New Zealand) and their extended family: Study protocol for a single-blind, randomised, non-inferiority trial. *Addiction* 2019; 114(2): 344-352.doi: 10.1111/add.14449
12. Thomas D, Farrell M, McRobbie H, Tutka P, Petrie D, West R, Siahpush M, Gartner C, **Walker N**, Mendelsohn C, Hall W, Paul C, Zwar N, Ferguson SG, Veronica B, Richmond R, Doran C, Shakeshaft A, Mattick R, Courtney R. The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: A study protocol for a randomised controlled non-inferiority trial. *Addiction* 2019 114(5): 923-933. doi: 10.1111/add.14541.
13. Nosa V, Leau K, **Walker N**. Cytisine as an alternative smoking cessation product for Pacific smokers in New Zealand. *Pacific Health Dialog* 2018: 21 (2): 89-95
14. Gartner C, Waa A, **Walker N**, Hao'uli S, Bonevski B. Introducing the SRNT Oceania chapter. *Nicotine Tob Res* [Editorial], 2018; 20(11): 1289–1291, <https://doi.org/10.1093/ntr/nty118>.
15. Castaldelli-Maia, J, Martins SS, **Walker, N**. The effectiveness of Cytisine versus Nicotine Replacement Treatment for smoking cessation in the Russian Federation: Cross-sectional study. [Short Report] *Int. J. Drug Policy*, 2018; 58: 121-125.
16. Bullen C, Verbiest M, Galea-Singer S, Kurdziel T, Laking G, Newcombe D, Parag V, **Walker N**. The effectiveness and safety of combining varenicline with nicotine e-cigarettes for smoking cessation in people with mental illnesses and addictions: Study protocol for a randomised-controlled trial. *BMC Public Health*, 2018; 18: 596. doi: 10.1186/s12889-018-5351-7
17. Guo CX, Anstice N, Babu RJ, Black, JM, Bobier WR, Lam CSY, Dai S, Gao TY, Hess, RF, Jenkins M, Jiang Y, Kowal L, Parag V, South J, Staffieri SE, **Walker N**, Wadham A, Thompson B on behalf of the Binocular Treatment of Amblyopia Using Videogames (BRAVO) Study Team. Optical treatment of amblyopia in older children and adults is essential prior to enrolment in a clinical trial. *Ophthalmic Physiol Opt* 2018; 38: 129–143. <https://doi.org/10.1111/opo.12437>
18. Gu Y, Doughty RN, Freedman B, Kennelly J, Warren J, Harwood M, Hulme R, Paltridge C, Teh R, Rolleston A, **Walker N**. Burden of Atrial Fibrillation in Māori and Pacific People in New Zealand: A Cohort Study. *Intern Med J* 2018, Mar;48(3):301-309. doi: 10.1111/imj.13648
19. Gao T, Guo CX, Babu RJ, Black JM, Bobier WR, Chakraborty A, Dai S, Hess RF, Jenkins M, Jiang Y, Kearns L, Kowal L, Lam CSY, Pang PCK, Parag V, Raveendren RN, South J, Staffieri SE, Wadham A, **Walker N**, Thompson B, on behalf of the BRAVO study team. Effectiveness of a Binocular Video Game vs

- Placebo Video Game for Improving Visual Functions in Older Children, Teenagers, and Adults With Amblyopia: A Randomized Clinical Trial. *JAMA Ophthalmol.* 2018;136(2):172–181. doi:10.1001/jamaophthalmol.2017.6090
20. Freedman B, Camm J, Calkins H, et al for the AF-Screen Collaborators. Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. *Circulation.* 2017; 135(19):1851-67 [Collaborator].
 21. Roberts V, Glover M, McCowan L, **Walker N**, Ussher M, Heke I, Maddison R. Exercise to support indigenous pregnant women to stop smoking: Acceptability to Māori. *Maternal Child Health J.* Published online first 12 July 2017.
 22. Cochran JR, Kydd RR, Lee JMJ, **Walker N**, Consedine NS. Disgust but not health anxiety graphic warning labels reduce motivated attention in smokers: a study of P300 and late positive potential responses. *Nicotine Tob Res* 2017 July; doi.org/10.1093/ntr/ntx158
 23. Bonevski B, Borland R, Paul S, Richmond R, Farrell M, Baker A, Gartner C, Lawn S, Thomas D, **Walker N**. No smoker left behind: Time for tackling tobacco in Australian priority populations [Opinion Piece]. *Med J Aust* 2017; 207(4): 141-2, doi: 10.5694/mja16.01425
 24. Taufa N, Laumatia A, Marsh S, **Walker N**, Whittaker R, Bullen C. Online Smoking Cessation Advertising and Young Pacific Smokers in New Zealand. *J Smoking Cess* 2017: 1-11. doi: 10.1017/jsc.2017.9
 25. Saxony J, Cowling L, Catchpole L, **Walker N**. Evaluation of a smoking cessation service in elective surgery. *J Surg Res* 2017; 212: 33-41.
 26. Guo CX, Babu RJ, Black, JM, Bobier WR, Lam CSY, Dai S, Gao TY, Hess, RF, Jenkins M, Jiang Y, Kowal L, Parag V, South J, Staffieri SE, **Walker N**, Wadham A, Thompson B. Binocular treatment of amblyopia using videogames (BRAVO): study protocol for a randomised controlled trial. *Trials* 2016; 17:504. doi: 10.1186/s13063-016-1635-3
 27. Donny E, **Walker N**, Hatsukami D, Bullen C. Reducing the nicotine content of combusted tobacco products sold in New Zealand. *Tob Control* 2016 doi:10.1136/tobaccocontrol-2016-053186.
 28. Humphrey G, Rossen F, **Walker N**, Bullen C. Parental smoking during pregnancy: Findings from the Growing Up in New Zealand Cohort. *NZ Med J* 2016; 129 (1442): 7019.
 29. Lucas NCC, **Walker N**, Bullen C. Using a videotaped objective structured clinical examination to assess knowledge in smoking cessation amongst medical students (the KISS study). *Med Teacher*, 2016; doi: 10.1080/0142159X.2016.1210116.
 30. Bollard T, Maubach N, **Walker N**, Ni Mhurchu C. Effects of plain packaging, warning labels, and taxes on young people's predicted sugar-sweetened beverage preferences: an experimental study. *Int J Behav Nutr Phys Activity*, 2016; 13: 95-101. Doi. 10.1186/s12966-016-0421-7.

31. **Walker N**, Bullen C, Barnes J, McRobbie H, Tutka P, Raw M, Etter J-F, Siddiqi K, Courtney, R, Castaldelli-Maia JM, Selby P, Sheridan J, Riggotti, N. Getting cytisine licensed for use worldwide: a call to action. [Editorial] *Addiction* 2016; 2016 Nov;111(11):1895-1898.
32. Kira A, Glover M, **Walker N**, Bauld, L. Recruiting pregnant indigenous women who smoke into a high contact incentivized cessation trial: a feasibility study. *Nicotine Tob Res* 2016; May, 1-5 first published online May 6, 2016 doi:10.1093/ntr/ntw106
33. Gu Y, **Walker N**, Humphrey G, Warren J, Kennelly J, Webster M, Rolleston A, Doughty RN. Uncontrolled hypertension prevalence, treatment and blood pressure levels: An analysis of New Zealand primary care data. *Heart Lung Circ* 2015; 24: S83-S84
34. Gu Y, Warren J, Kennelly J, **Walker N**, Harwood M. Incidence rate of prediabetes: an analysis of New Zealand primary care data. *Stud Health Tech Inform* 2015; 214:81-6.
35. **Walker N**, Fraser T, Howe C, Laugesen M, Truman P, Parag V, Glover M, Bullen C. Abrupt nicotine reduction as an endgame policy: a randomised trial. *Tob Control*. 2015; 24 (e4); e251-e257.
36. Newcombe D, Sheridan J, **Walker N**, Galea, S. The effect of varenicline administration on cannabis and tobacco use in cannabis and nicotine dependent individuals - a case-series. *J Addict Res Theory*, 2015; 6: 222. doi: 10.4172/2155-6105.1000222
37. O'Brien B, Knight-West O, **Walker N**, Bullen C. E-cigarettes for smoking cessation in people with mental illness: Secondary analysis of data from the ASCEND trial. *Tob Induced Dis* 2015. **13**:5 doi:10.1186/s12971-015-0030-2. [Highly accessed]
38. White J, Walton D, **Walker N**. Exploring comorbid use of marijuana, tobacco, and alcohol among 14 to 15-year-olds: findings from a national survey on adolescent substance use. *BMC Public Health* 2015, 15:233. doi: 10.1186/s12889-015-1585-9.
39. **Walker N**, Howe C, Glover M, McRobbie H, Barnes J, Nosa V, Parag V, Bassett B, Bullen C. Cytisine versus nicotine for smoking cessation. *New Engl J Med* 2014; 371:2353-2362.
40. Glover M, Kira A, **Walker N**, Bauld L. Using Incentives to Encourage Smoking Abstinence Among Pregnant Indigenous Women? A Feasibility Study. *Maternal Child Health* 2014; 19 (6): 1393-1399
41. Glover M, Kira A, Johnston V, **Walker N**, Brown N, Thomas D. Australian and New Zealand Indigenous mothers' report respect for smoking bans in homes. *Women Birth* 2014; available online 8th November. [10.1016/j.wombi.2014.09.004](https://doi.org/10.1016/j.wombi.2014.09.004)
42. **Walker N**, Johnston J, Glover M, Bullen C, Trenholme A, Chang A, Morris P, Segan C, Brown N, Fenton D, Hawthorne E, Borland R, , Parag V, von

- Blaramberg T, Westphal D, Thomas D. Effect of a family-centred environmental tobacco smoke intervention to reduce respiratory illness in Indigenous infants: a randomised trial. *Nicotine Tob Res* 2014; doi: 10.1093/ntr/ntu128.
43. Glover M, Kira A, Johnston V, **Walker N**, Thomas DP, Chang AB, Bullen C, Segan C, Brown N. A systematic review of barriers and facilitators to participation in randomized controlled trials by Indigenous people from New Zealand, Australia, Canada and the United States. *Global Health Prom* 2015; 22(1); 21-31.
 44. Deal H, Newcombe D, **Walker N**, Galea S. Smoking Cessation in a Community Alcohol and Drug Service: Acceptability and Feasibility. *Addict Disorders Treat*. 2014; 13(4):199-209.
 45. Gu Y, Warren J, **Walker N**, Kennelly J. Gender differences in cardiovascular disease risk management for Pacific people in New Zealand general practice. *Qual Prim Care*, 2013; 21: 275-85
 46. Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, **Walker N**. Electronic cigarettes for smoking cessation: a randomised controlled trial. *Lancet* 2013; 382: 1629–37. [highly accessed]
 47. Li J, Bullen C, Newcombe R, **Walker N**, Walton D. The use and acceptability of electronic cigarettes in New Zealand smokers. *NZ Med J* 2013, 31 May, Vol 126 No 1375; ISSN 1175 8716.
 48. Bullen C, Williman J, Howe C, Laugesen M, McRobbie H, Parag V, **Walker N**. Study protocol for a randomised controlled trial of electronic cigarettes versus nicotine patch for smoking cessation. *BMC Public Health* 2013, 13:210 doi:10.1186/1471-2458-13-210 [Highly accessed]
 49. Johnston V, Westphal D, Glover M, Thomas DP, Segan C, **Walker N**. Reducing smoking among indigenous populations: New evidence from a review of trials. *Nicotine Tob Res* 2013; 15(8): 1329-1338
 50. Jull AB, Rodgers A, **Walker N**. Honey as a topical treatment for wounds. *Cochrane Database Syst Rev*, The Cochrane Library; Issue 2, 2015. DOI: 10.1002/14651858.CD005083.pub3. [Top five most frequently downloaded updated Cochrane Reviews published in 2015]
 51. Renner K, **Walker N**, Parag V, McCormick R. Harm Reduction Text Messages Delivered During Alcohol Drinking: Feasibility Study Protocol. *JMIR Res Protoc* 2012;1(1):e4. doi:10.2196/resprot.1970.
 52. **Walker N**, Howe C, Bullen C, Grigg M, Glover M, McRobbie H, Laugesen M, Parag V, Whittaker R. The combined effect of very low nicotine content cigarettes, used as an adjunct to usual Quitline care (nicotine replacement therapy and behavioural support) on smoking cessation: a randomized controlled trial. *Addiction* 2012; 107 (10); 1857–1867.
 53. **Walker N**, Howe C, Bullen C, McRobbie H, Glover M, Parag V, Williman J, Veale R, Nosa V, Barnes J. Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking. *BMC Public Health* 2011; 11; 880.

54. **Walker N**, Williman J, Sheriden J, Newcombe D, McRobbie H, Galea S. Nicotine receptor partial agonists for alcohol dependence [Protocol]. *Cochrane Database Syst Rev*, The Cochrane Library; issue 12, 2011.
55. **Walker N**, Howe C, Bullen C, Grigg M, Glover M, McRobbie H, Laugesen M, Jaing J, Chen M-H, Whittaker R, Rodgers A. Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomised controlled trial. *Addiction*, 2011; 106 (6): 1176-1185.
56. Thompson-Evans T, Glover M, **Walker N**. Cytisine's potential to be used as a traditional healing method to help indigenous people stop smoking: A qualitative study with Māori. *Nicotine Tob Res* 2011; 13 (5): 353-360.
57. **Walker N**, Howe C, Bullen C, Grigg M, Glover M, McRobbie H, Laugesen M, Vander Hoorn S, Whittaker R. Study protocol for a randomised trial of nicotine-free cigarettes as an adjunct to usual NRT-based cessation practice in people who wish to stop smoking. *BMC Public Health* 2011 11:37: doi:10.1186/1471-2458-11-37.[Highly accessed]
58. Bullen C, Howe C, Lin R-B, Grigg M, Laugeson M, McRobbie H, Glover M, **Walker N**, Wallace-Bell M, Whittaker R. Pre-cessation nicotine replacement therapy. Pragmatic randomised trial. *Addiction* 2010; 105(8):1474-83.
59. Barnes J, Dong CY, White A, **Walker N**, Stead L. Hypnotherapy for smoking cessation. *Cochrane Database Syst Rev*, The Cochrane Library 2010, Issue 10. Art. No.: CD001008.
60. Johnston V, **Walker N**, Thomas D, Glover M, Chang A, Bullen C, Morris P, Brown N, Vander Hoorn S, Borland R, Segan C, Trenholme A, Mason T, Fenton D, Ellis K. The study protocol for a randomized controlled trial of a family-centred tobacco control program about environmental tobacco smoke (ETS) to reduce respiratory illness in Indigenous infants. *BMC Public Health* 2010, 10:114
61. Watson D, Bullen C, Glover M, McRobbie H, Parag V, **Walker N**. Impact on quit attempts of mailed general practitioner 'brief advice' letters plus nicotine replacement therapy vouchers. *J Prim Health Care* 2010; 2(1): 4-10
62. Jull A, Parag V, **Walker N**, Rodgers A. Responsiveness of generic and disease specific health related quality of life instruments to venous leg ulcer healing. *Wound Repair Regen* 2010; 18: 26 – 30.
63. **Walker N**, Bullen C, McRobbie H. Reduced nicotine cigarettes as an aid to smoking cessation. *Nicotine Tob Res* 2009; 11(11):1274 - 1279.
64. Jull A, Parag, V, **Walker N**, Maddison R, Kerse N, Johns T. A pilot randomised controlled trial of home-based progressive resistance exercises for treating venous leg ulcers: The PREPARE pilot. *J Wound Care* 2009; 18(12): 497 – 503.
65. Jull A, **Walker N**, Parag V, Molan P, Rodgers A, on behalf of the Honey as Adjuvant Leg Ulcer Therapy trial collaborators. Usual care versus guideline recommendations for venous ulcer management in New Zealand. *NZ Med J* 2009; Vol 122 (1295): 9-18.

66. McRobbie H, Bullen C, **Walker N**, Whittaker R, Glover M, Fraser T. New Zealand smoking cessation guidelines. *NZ Med J* 2008;121:57-70.
67. Thornley S, McRobbie H, Eyles H, **Walker N**, Simmons G. The obesity epidemic: is glycemic index the key to unlocking a hidden addiction? *Med Hypoth* 2008; 71: 709 - 714.
68. Jull AB, Rodgers A, **Walker N**. Honey as a topical treatment for wounds. *Cochrane Database of Systematic Reviews* 2008, Issue 1. Art. No. CD005083.
69. Bullen C, **Walker N**, Whittaker R, McRobbie H, Glover M, Fraser T. Smoking cessation competencies for health workers in New Zealand. *NZ Med J* 2008, 20 June.
70. Cooke F, Bullen C, Whittaker R, McRobbie H, Chen M-H, **Walker N**. Diagnostic accuracy of NicAlert™ Cotinine Test Strips in saliva for verifying smoking status. *Nicotine Tob Res* 2008; 10 (4); 607 - 612.
71. Jull A, **Walker N**, Parag V, Molan P, Rodgers A on behalf of the Honey as Adjuvant Leg Ulcer Therapy trial collaborators. Randomised clinical trial of honey-impregnated dressings for venous leg ulcers. *Brit J Surg* 2008; 95: 175-182.
72. Dalziel SR, Rea HH, **Walker N**, Parag V, Mantell C, Rodgers A, Harding JE. Long-term effects of antenatal betamethasone on lung function: 30-year follow up of a randomised controlled trial. *Thorax*, 2006; 61 (8): 678-683.
73. Bullen C, Whittaker R, **Walker N**, Wallace-Bell M. Pre-quitte nicotine replacement therapy: Findings from a pilot study. *Tob Induced Dis* 2006; 3(2): 35-40.
74. Dalziel SR, **Walker N**, Parag V, Mantell C, Rea HH, Rodgers A, Harding JE. Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. *Lancet*, 2005; 365(9474): 1856-1862.
75. Jull AB, Rodgers A, **Walker N**. Honey as a topical treatment for wounds [Protocol]. *Cochrane Wounds Group, Cochrane Database Syst Rev, The Cochrane Library*, 2005; Issue 2.
76. Jull A, **Walker N**, Hackett M, Jones M, Rodgers A, Birchall N, Norton R, MacMahon S. Leg ulceration and perceived health: a population-based case-control study. *Age Ageing* 2004; 33: 236-241.
77. Jull AB, Mitchell N, Arroll J, Jones M, Waters J, Latta A, **Walker N**, Arroll B. Factors influencing concordance with compression stockings after venous ulcer healing. *J Wound Care*, 2004; 13(3): 90-92.
78. **Walker N**, Rodgers A, Birchall N, Norton R, MacMahon S. Leg ulceration as a long-term complication of deep vein thrombosis. *J Vasc Surg* 2003; 38: 1331-1335.
79. McLaughlin K, Crowther C, **Walker N**, Harding J. Effects of a single course of corticosteroids given more than seven days before birth: a systematic review. *Aust NZ J Obstet Gynecol* 2003; 43: 101-106.
80. **Walker N**, Vandal A, Holden J, Rodgers A, Birchall N, Norton R, Triggs C, MacMahon S. Does capture-recapture analysis provide more reliable estimates

of the incidence and prevalence of leg ulcers in the community? Aust NZ J Public Health 2002; 26(5): 451 – 455.

81. **Walker N**, Rodgers A, Birchall N, Norton R, MacMahon S. Leg ulcers in New Zealand: age at onset, recurrence and provision of care in an urban population. NZ Med J 2002; 115: 286 - 289.
82. **Walker N**, Rodgers A, Gray H. Changing patterns of pharmacological thromboprophylaxis use by orthopaedic surgeons in New Zealand. Aust NZ J Surg. 2002; 72(5): 335 – 338.
83. **Walker N**, Rodgers A, Birchall N, Norton R, MacMahon S. The occurrence of leg ulcers in Auckland: results of a population-based study. NZ Med J 2002; 115 (1151): 159 - 162.
84. Rodgers A, **Walker NK**, Schug SA, McKee A, Van Zundert A. Reduction of postoperative mortality and morbidity – Reply. BMJ 2001; 322; 1182 - 1183
85. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: the Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295 – 1302.
86. Rodgers A, **Walker N**, Schug S, McKee A, Kehlet H, van Zundert A, Sage D, Futter M, Saville G, Clark T, MacMahon S. Reduction of post-operative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ 2000; 321: 1493 - 1505.
87. **Walker N**, Norton R, Vander Hoorn S, Rodgers A, MacMahon S, Clark T, Gray H. Mortality after hip fracture: regional variations in New Zealand. NZ Med J 1999; 112 (1092): 269 - 272.
88. Eberhart-Phillips J, **Walker N**, Garrett N, Bell D, Sinclair D, Rainger W, Bates M. Campylobacteriosis in New Zealand: Results of a case-control study. J Epid Community Health 1997; 51(6): 686 – 691.
89. Brown TJ, Hastie JC, Kelly PJ, van Duivenboden R, Ainge J, Jones N, **Walker NK**, Till DG, Sillars H, Lemmon F. The presence and distribution of *Giardia* cysts in New Zealand waters. N Z J Marine Freshwater Res 1992; 26: 279 - 282.

Letters to the Editor:

1. **Walker N**, Parag V, Verbiest M, Laking G, Laugesen M, Bullen C. Nicotine patches with e-cigarettes for smoking cessation: twitter discussion from a respiratory journal club – Authors' reply. [letter]. *Lancet Resp Med* 2020; March: [https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(20\)30073-4/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30073-4/fulltext)[https://doi.org/10.1016/S2213-2600\(20\)30073-4](https://doi.org/10.1016/S2213-2600(20)30073-4)
2. Shahab L, Britton J, Brown J, Hajek P, McNeill A, on behalf of 33 signatories. The need for an evidence-based and rational debate on e-cigarettes. [letter] *Lancet* 2020; 395: 688.
3. **Walker N**, Doughty R, Parag V, Harrison J, Bennett M, Freedman B. Pharmacy-based screening for Atrial Fibrillation in high-risk Maori and Pacific [letter]. *NZ Med J*, 2014; 127 (1398): 128-131.
4. Bullen C, Knight-West O, O'Brien B, **Walker N**. Evidence, not conjecture, should guide clinical practice and policies on e-cigarettes. *BMJ* 2014;348:g2008. Letter in response to "Detrimental effects of e-cigarettes on surgical outcomes & dangers of using e-cigarettes before anaesthesia." *BMJ* 2014;348:g1156
5. Knight-West O, O'Brien B, **Walker N**, Bullen C: Context on Use Is Needed Before Public Health Recommendations Are Made About E-Cigarettes. *Am J Prevent Med* 2014, 46:e57-e58.
6. Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, **Walker N**. Electronic cigarettes and smoking cessation: a quandary? – Authors' reply. *Lancet* 2014; 83(9915):408–409.
7. Williman J, Fernandes K, **Walker N**, Bullen C. Promotion of nicotine replacement therapy and smoking cessation services by grocery stores [letter]. *NZ Med J* 2011; 124 (1333): 65-7. ISSN 1175 8716 URL: <http://www.nzma.org.nz/journal/124-1333/4643/>
8. Bullen C, McRobbie H, Thornley S, **Walker N**, Whittaker R. Working with what we have before getting into bed with the tobacco industry [letter]. *NZ Med J* 2006; 119(1240): 2139.
9. **Walker N**, Rodgers A, Birchall N, Norton R, MacMahon S. Pregnancy and leg ulceration [letter]. *J Wound Care* 2004; 13(1): 20.
10. Rodgers A, **Walker N**, Bennett D, Schug S. Need for an updated overview to assess the benefits of epidurals [letter]. *Anesth Analg* 2003; 97(3): 923-924.

Reports:

1. Smokefree Expert Advisory Group. Discussion paper on vaping and e-cigarette regulation. Health Coalition Aotearoa. March 2020.
2. **Walker N**, McCormack J, Jiang, Y, Lang B, Ni Murchu C. (2019). Energy labelling for alcoholic beverages in New Zealand: Clinical trial. Phase 2 report: Wellington: Health Promotion Agency.

3. **Walker N**, McCormack J, Jiang, Y, Lang B, Ni Murchu C. (2019). Energy labelling for alcoholic beverages in New Zealand: Consumer perceptions. Phase 1 report: Focus Groups. Wellington: Health Promotion Agency. ISBN:978-0-478-44956-3.
4. Newcombe DAL, Paull N, Rawston J, Sheridan J, **Walker N**. Scoping a New Zealand Drug Early Warning System: A review of existing global monitoring systems [Report]. 2017. The Centre for Addiction Research. The University of Auckland.
5. Edwards R, Bullen C, **Walker N**, Hoek J, Beaglehole R. Background paper: E-cigarettes and their potential contribution to achieving the Smokefree 2025 goal. Prepared for the National Smokefree Working Group, August 18, 2016.
6. Edwards R, Bullen C, **Walker N**, Hoek J, Beaglehole R. Policy briefing on e-cigarettes for Associate Minister of Health, Hon. Peta Sam Lotu-Liga, August 2016.
7. **Walker N**, Galea-Singer J, Newcombe D, Bullen C, Galea S. High-dose, personalized, long-term nicotine substitution for alcohol and other drug dependent smokers (HD NRT): A Feasibility Study. National Institute for Health Innovation, Auckland, 2016.
8. Humphrey G, Bullen C, Rossen F, **Walker N**. Parental smoking during pregnancy: Findings from the Growing Up in New Zealand Cohort. Prepared for Katherine Clarke, Whakawhetū, National Manager, Maori Health Service Programme. National Institute for Health Innovation, December 2015.
9. Humphrey G, Marsh, S, **Walker N**, Knight-West O. Evaluation of a Smoking Cessation Programme for Waitemata DHB Mental Health Services [Confidential report]. National Institute for Health Innovation, 2015.
10. Humphrey G, Kolston J, Gu H, Webster M, **Walker N**, Doughty RN. Uncontrolled and Resistant Hypertension: A Systematic Review. National Institute for Health Innovation, 2015.
11. Lawes C, Doughty R, Rolleston A, **Walker N**. Cardiovascular Disease in New Zealand 2014: A summary of recent statistical information. National Institute for Health Innovation, 2015.
12. **Walker N**, Von Blaraberg T, Mackay J, McNaughton W, Strickland J, Van Mil J, Bettle E, Power K, Parore M, Parag V, Bullen C. He Tapu Te Hā: Space to Breathe: Effectiveness of preschool asthma education: a community-based, cluster randomised controlled trial in children aged 2 to 5 years with diagnosed asthma or at high risk of asthma. PHARMAC report, Wellington, 2014.
13. Williman, J, **Walker N**. SPINS: Supermarket promotion to increase NRT purchases. Report for the Ministry of Health. University of Auckland, Auckland, 2011
14. Deal H, **Walker N**, Newcombe, D. Nicotine Choice Evaluation (NICHE) Study. Report for the Ministry of Health. University of Auckland, Auckland, 2011.

15. **Walker N.** Investigators Brochure: ReCharge: An ice-cream to support patients receiving cancer treatment. Document written for Lactopharma, New Zealand, 2009.[Confidential]
16. Bullen C, Fraser T, Glover M, McRobbie H, **Walker N**, Whittaker R. 'A *Smoking Cessation Training Framework*.' A report commissioned by the New Zealand Ministry of Health, Wellington. January 2008. 1-18.
17. Bullen C, Fraser T, Glover M, McRobbie H, **Walker N**, Whittaker R. 'Smoking Cessation Competencies for New Zealand.' A report commissioned by the New Zealand Ministry of Health, Wellington. August, 2007. ISBN .978-0-478-19169-1 (print) ISBN 978-0-478-19170-7 (online). 14 pages.
18. Eberhart-Phillips J, **Walker N**, Garrett N, Bell D, Sinclair D, Rainger W, Bates M. Campylobacteriosis in New Zealand: Results of the MAGIC Study. Ministry of Health and Public Health Commission, 1996. ISBN: 0-478-09439-6.
19. **Walker N**, Baker M. Utilisation of the needle exchange programmes in New Zealand. Annual update: January –December 1994. ESR: Health Communicable Disease Centre, 1995.
20. **Walker N**, Baker M. Utilisation of the needle exchange programmes in New Zealand. Update: January –June 1994. ESR: Health Communicable Disease Centre, 1995.
21. **Walker N**, Chereshtsky A, van Duivenboden R, Bates M. Proposal for a case-control study of legionellosis risk factors in New Zealand, May 1995. ESR: Health Communicable Disease Centre, 1995.
22. **Walker N**, Brady H, Baker M. Analysis of returned syringes to map the regional distribution of HIV markers in New Zealand injecting drug user populations, 1994. ESR: Health Communicable Disease Centre, 1994.
23. **Walker N**, Malcolm M, Weekes P, Bates M. Survey of hospital infection control programmes in New Zealand (May 1994). ESR: Health Communicable Disease Centre, 1994.
24. **Walker N**, Baker M. Utilisation of the needle exchange programmes in New Zealand (1988 – 1993). ESR: Health Communicable Disease Centre, 1994.

Other works:

1. **Walker, N.** (2020). [podcast] Nicotine patches, e-cigarettes, and smoking cessation. Available at: https://www.thelancet.com/pb-assets/Lancet/stories/audio/lanres/2019/TLRM_Sept_19_E-cigarettes.mp3 [Accessed 19 Feb. 2020].
2. White S, Bullen C, **Walker N**. Opportunistic provision of smoking cessation support at Starship Children's Hospital's emergency department. *Addiction Research Bulletin*. 2017; 20 (3); November.

3. **Walker N**, West R, Raw M, Etter J-F. Cytisine for smoking cessation. April 2016, Update to website <http://www.treatobacco.net> [in English, French and Spanish]
4. **Walker N**, et al. Abstract of “**Walker N**, Howe C, Bullen C, Grigg M, Glover M, McRobbie H, Laugesen M, Parag V, Whittaker R. The effect of very low nicotine content cigarettes, used as an adjunct to nicotine replacement therapy, on smoking cessation: a randomised controlled trial. *Addiction* 2012; 107 (10); 1857–1867. doi:10.1111/j.1360-0443.2012.03906.x” in *Psychology Progress since April 17 2013*.
5. Sheridan J, **Walker N**. Support for Smoking Cessation. *Pharmacy Today*, June 2010.
6. **Walker N**, Bullen C. Bioresonance therapy for smoking – miracle cure or con? *New Zealand Skeptics Magazine Winter 2009, issue 92; 3 – 7*.
7. Jull, A et al. Extended abstract of “Jull A, **Walker N**, Parag V, Molan P, Rodgers A on behalf of the Honey as Adjuvant Leg Ulcer Therapy trial collaborators. Randomised clinical trial of honey-impregnated dressings for venous leg ulcers. *Brit J Surg* 2008; 95: 175-182” in *Phlebology Digest* 2008; 21(2):24 – 27.
8. Jull, A et al. Extended abstract of “Jull A, **Walker N**, Parag V, Molan P, Rodgers A on behalf of the Honey as Adjuvant Leg Ulcer Therapy trial collaborators. Randomised clinical trial of honey-impregnated dressings for venous leg ulcers. *Brit J Surg* 2008; 95: 175-182” with commentary in *Evidence-based Nursing* 2008; 11:87.
9. **Walker N**. Extended abstract of “**Walker N**, Rodgers A, Birchall N, Norton R, MacMahon S. The occurrence of leg ulcers in Auckland: results of a population-based study. *NZ Med J*; 2002: 115 (1151): 159 - 162” in *Phlebology Digest* 2003; 16(2); 20.
10. **Walker N**. Epidemiological studies of leg ulcers in Auckland, New Zealand. University of Auckland, Auckland, 2001, PhD in Medicine.
11. Jull AB, Waters J, Arroll B, Latta A, Bouchier R, **Walker N**, Oliver F, Milne R, Gelber P, Tuuta N. Guidelines for management of people with chronic leg ulcer. NZ Centre for Evidence Based Nursing: Auckland. 2000.
12. **Walker NK**. Cyanobacteria-like bodies as a cause of diarrhoea. *CDNZ* 1993; 93(3): 43 - 44.
13. **Walker NK**. Laboratory surveillance of giardiasis and cryptosporidiosis in New Zealand. *CDNZ* 1992; 92(3): 25.
14. **Walker NK**. *Giardia* and *Cryptosporidium* in drinking water. *CDNZ* 1992; 92(10): 97 - 98.
15. **Walker N**, Wilson N, Till D. Testing for giardiasis in New Zealand. *CDNZ* 1991; 91(6): 59 - 61.
16. Ionas G, Kelly PJ, **Walker NK**. A new test for the detection of *Giardia*. *CDNZ* 1991; 91(12): 113 - 114.

17. Stehr-Green J, Sim J, **Walker N**, Patel V. Cluster of giardiasis in Whitby. CDNZ 1991; 91(1): 4 - 6.
18. **Walker N**, Wilson N, Till D. Giardiasis in New Zealand: results of a laboratory-based survey. NZ J Med Lab Science 1991; 45(2): 45 - 47.